The report outlined three key insights from the study:

GLP-1s drive a historic shift in traditional drug spending increases. Consumer adoption has surged, with nearly one-third of commercially insured households reporting that they or a household member has used GLP-1s. The primary reason for use was weight loss, with 58% of respondents using GLP-1s personally and 51% reporting use by a household member. Claims data also show rapid adoption of GLP-1 for weight loss, with a steady increase in utilization since 2021 and peaking at 213.8% in 2023.
GLP-1s face dual challenges of rapid uptake and high discontinuation rates, raising questions about long-term value. Although GLP-1 usage has surged, many individuals discontinue treatment prematurely. Previous analysis indicated that more than 50% of patients using GLP-1s for weight loss stopped treatment within 12 months. This high discontinuation rate significantly affects clinical outcomes and long-term drug-utilization trends.
Surging GLP-1 use among young people amplifies sustainability and supply concerns. Early adoption of costly treatment can create an unsustainable burden on health plans, employers and communities because of potential lifelong reliance and the related comorbidities of these costly treatments. Employers and health plans should consider a balanced approach that prioritizes lifestyle interventions, such as increasing physical activity, improving diet and reducing screen time, along with community- and system-level initiatives. These could help reverse this trend and possibly eliminate the need for medications.

Instant Insights /

Weight management drugs now lead drug spending increases, study finds

More From HR Executive

Related Stories

Recommended For You